QuantumPharm, Inc. (2228) AI Stock Analysis

• Market Cap: HK$42.04B
• Dividend Yield: N/A
• Average Volume (3M): 190.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 50.10%
• EPS Growth: -212.76%
• Country: HK
• Employees: 809
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.02
• Shares Outstanding: 4,017,001,700
• 10 Day Avg. Volume: 284,839,556
• 30 Day Avg. Volume: 190,341,685
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$10.50
• Price Target Upside: 2.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: HK$10.50 ▲(2.14% Upside)

QuantumPharm, Inc. receives a moderate score due to strong technical momentum, despite significant financial challenges. The company's inability to generate profits and negative cash flows weigh heavily on its financial performance. While technical indicators suggest bullish trends, overbought conditions may pose risks. Valuation concerns further impact the overall score.

Positive Factors

Financial Strength

The company further strengthened its financial position by completing two fundraising placements raising HK$3.2bn to enhance its cash reserves and fund future growth initiatives.

Partnerships

XtalPi's expanding ecosystem of partnerships reflects its strong commercialization potential across AI and robotics-enabled industries.

Revenue Growth

XtalPi leverages its proprietary AI-powered R&D platform to deliver stable and accelerating revenue growth across two core business areas: drug discovery and intelligent robotics.

Negative Factors

Commercialization Sustainability

Risks relating to R&D progress of drug candidates in partnerships, sustainability of commercialization, and shareholder sell-off.

R&D Pipeline Risks

Risks include potential delays in partnered R&D pipelines, uncertainty in commercialization sustainability, and possible sell-off following lock-up expiry.

QuantumPharm, Inc. Business Overview & Revenue Model

Company Description

XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

How the Company Makes Money

QuantumPharm, Inc. generates revenue primarily through the commercialization of its proprietary pharmaceutical products. Key revenue streams include the sale of approved therapeutics, licensing agreements for its advanced drug discovery technologies, and partnerships with pharmaceutical companies for collaborative research and development. Additionally, the company may receive milestone payments and royalties from licensed products developed using its technology platforms. Strategic alliances with research institutions and biotech firms further contribute to its earnings by expanding its technological reach and market presence.

QuantumPharm, Inc. Financial Statement Overview

Summary

QuantumPharm, Inc. shows strong revenue growth, but persistent losses and negative cash flows are concerning. Improvements in debt and equity offer some stability, but profitability and cash flow issues remain critical challenges.

Income Statement

QuantumPharm, Inc. has shown significant revenue growth from 2019 to 2024, yet the company struggles with profitability. Gross Profit Margin improved to 46.31% in 2024 from 27.66% in 2023, but the company continues to incur substantial net losses, with a Net Profit Margin of -569.33% in 2024. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has made notable improvements in its balance sheet, reducing total debt significantly from 2023 to 2024. The Debt-to-Equity Ratio has improved due to a positive equity position in 2024. However, the Equity Ratio remains a concern, reflecting potential financial instability.

Cash Flow

Operating Cash Flow has improved slightly, yet remains negative, impacting the company's ability to generate positive Free Cash Flow. Despite the improvement in financing activities, the Free Cash Flow to Net Income Ratio remains unfavorable, indicating ongoing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	266.43M	174.42M	133.35M	62.80M	0.00
Gross Profit	123.43M	48.24M	66.09M	32.78M	0.00
EBITDA	-631.38M	-1.78B	-390.37M	-2.11B	-9.84M
Net Income	-1.52B	-1.91B	-1.44B	-2.14B	-36.03M
Balance Sheet
Total Assets	4.35B	4.01B	4.32B	4.38B	8.44M
Cash, Cash Equivalents and Short-Term Investments	3.10B	2.83B	3.47B	3.83B	8.44M
Total Debt	148.76M	11.04B	9.45B	7.83B	159.05M
Total Liabilities	362.43M	11.25B	9.63B	7.99B	219.45M
Stockholders Equity	3.96B	-7.27B	-5.33B	-3.61B	-211.01M
Cash Flow
Free Cash Flow	-536.79M	-698.20M	-627.83M	-417.42M	655.00K
Operating Cash Flow	-478.68M	-567.56M	-429.10M	-253.75M	655.00K
Investing Cash Flow	74.09M	735.58M	-2.76B	-70.47M	33.00K
Financing Cash Flow	840.00M	-25.89M	57.99M	2.48B	0.00

QuantumPharm, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Positive. The current price of 10.28 is above the 20-day moving average (MA) of 8.23, above the 50-day MA of 6.78, and above the 200-day MA of 5.73, indicating a bullish trend. The MACD of 1.07 indicates Negative momentum. The RSI at 77.28 is Negative, neither overbought nor oversold. The STOCH value of 79.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2228.

QuantumPharm, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	67 Neutral	HK$69.74B	48.55	19.62%	―	―	―
2502	61 Neutral		7.33	-1.60%	4.39%	30.77%	-128.09%
2228	56 Neutral	HK$42.04B	―		―	50.10%	-212.76%
Sector *	56 Neutral	$6.56B	-0.98	0.45%	6.27%	14.92%	10.98%
2509	55 Neutral		―	-64.62%	―	―	―
2498	52 Neutral	HK$18.45B	―	-10.42%	―	―	―
2511	36 Underperform	HK$1.94B	―	-67.27%	―	―	47.42%

QuantumPharm, Inc. Corporate Events

XtalPi Holdings Announces Significant Financial Turnaround in H1 2025

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant improvement in its financial performance for the first half of 2025. The company expects a substantial increase in revenue and a turnaround from a net loss to a net profit, primarily driven by its collaboration with DoveTree Medicines LLC using its AI drug discovery platform. This marks the first time the company has achieved half-year profits, indicating a positive shift in its operational and financial trajectory.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi and DoveTree Enter Definitive Agreement for AI-Driven Drug Discovery

XtalPi Holdings Limited, through its subsidiary Shenzhen XtalPi Technology Co., Ltd., has entered into a definitive agreement with DoveTree Medicines LLC to leverage its AI drug discovery platform for developing small molecule and antibody drug candidates. This collaboration focuses on oncology, immunologic and inflammatory diseases, neurological disorders, and metabolic dysregulation, with DoveTree obtaining exclusive development and commercialization rights. The agreement includes an initial payment of $51 million to XtalPi, with potential further payments and royalties based on product sales.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Partners with DoveTree for AI-Driven Drug Discovery

XtalPi Holdings Limited has entered into a term sheet with DoveTree LLC to collaborate on drug discovery using its AI and robotics platform. This partnership will focus on developing small molecule and antibody drug candidates for tumors, autoimmune, and neurological diseases, potentially leading to significant financial gains and global commercialization rights for DoveTree.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Co-Founders Extend Lock-Up, Signaling Confidence

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its co-founders have voluntarily extended their lock-up undertakings for another year, demonstrating their confidence in the company’s long-term value and future prospects. This extension involves a total of 591,488,405 shares, representing 14.71% of the issued share capital, and is seen as a positive signal for stakeholders, potentially stabilizing the company’s stock and reinforcing its market position.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.